New Drug BI 456906 Explored for Obesity, Compared to Semaglutide
Background
Obesity is a complex chronic disease affecting millions globally, significantly increasing the risk of conditions like type 2 diabetes and cardiovascular disease. Current treatments, such as semaglutide (a GLP-1 receptor agonist), have shown efficacy by targeting specific metabolic pathways. However, there's a continuous need for novel therapeutic strategies that might offer improved or complementary mechanisms of action. This Phase I clinical trial addresses the knowledge gap regarding how a new compound, BI 456906, specifically interacts with glucagon receptors in the liver compared to semaglutide's known action on GLP-1 receptors.
Results
This ongoing Phase I study, which began recruiting in October 2024 and is estimated to complete by December 2026, aims to precisely quantify the receptor occupancy of BI 456906 and semaglutide in specific organs. Researchers will use advanced PET/CT and MRI imaging with radiolabeled tracers to measure the binding of these compounds to glucagon receptors (which regulate glucose metabolism) in the liver and GLP-1 receptors (involved in insulin secretion and satiety) in the pancreas. The study's primary goal is to determine if BI 456906 exhibits a distinct and measurable occupancy profile at glucagon receptors in the liver compared to semaglutide, which primarily targets GLP-1 receptors. > The most critical expected outcome is the detailed mapping of BI 456906's specific binding to glucagon receptors in the liver, providing insights into its potential unique mechanism of action for obesity treatment and metabolic regulation.
Why It Matters
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct glucagon receptor occupancy in the liver, it could represent a new mechanistic approach to metabolic disease management, potentially offering advantages or complementary effects to existing GLP-1 receptor agonists like semaglutide. This Phase I study is foundational, providing essential pharmacokinetic and pharmacodynamic data necessary for advancing BI 456906 into Phase II clinical trials, where its efficacy and safety in a larger patient population would be assessed.